Merrimack Names CFO
This article was originally published in Scrip
Merrimack Pharmaceuticals, Inc. has named Dr Yasir Al-Wakeel chief financial officer and head of corporate development – effective from Aug. 11, 2015. Al-Wakeel will serve a key role in continuing to build Merrimack into a fully integrated cancer company based on a systems engineering approach, the company noted. Merrimack currently has a pipeline of oncology candidates led by MM-398 (irinotecan liposome injection), which is currently under FDA review for approval in post-gemcitabine metastatic pancreatic cancer. Prior to joining Merrimack, Al-Wakeel was a director on the healthcare investment banking team at Credit Suisse.
You may also be interested in...
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.
Experts discuss the future of brain health, changing the stereotypical view of an Alzheimer’s patient and how technology and science have evolved the treatment possibilities for dementia patients in 2020 – even if ‘clinical practice is taking a long time to catch up.’
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.